Pancreatic Cancer Research

ResearcherNational Cancer Center Research InstituteNo recent work listed

Yoshinori Ino

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5078011405. Sources: OpenAlex.

Their work

Papers
10 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
28
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 1 paper

Papers 10

  1. Neoadjuvant therapy alters the collagen architecture of pancreatic cancer tissue via Ephrin-A5. First author DOI 10.1038/s41416-021-01639-9↗
  2. Expression of classical human leukocyte antigen class I antigens, HLA-E and HLA-G, is adversely prognostic in pancreatic cancer patients. First author DOI 10.1111/cas.14514↗
  3. Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. First author DOI 10.1371/journal.pone.0242851↗
  4. A Novel Role of Interleukin 13 Receptor alpha2 in Perineural Invasion and its Association with Poor Prognosis of Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12051294↗
  5. Reliable evaluation of tumor-infiltrating lymphocytes in pancreatic cancer tissue biopsies. Co-author DOI 10.18632/oncotarget.26646↗
  6. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
  7. Macroscopic features predict outcome in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00428-016-2026-6↗
  8. Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer. First author DOI 10.1038/bjc.2015.145↗
  9. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Co-author DOI 10.1038/bjc.2013.32↗
  10. Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055146↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuaki Shimada · 9 shared papers, 2013–2022 · strength 0.74
  2. Nobuyoshi Hiraoka · 9 shared papers, 2013–2022 · strength 0.74
  3. Yoji Kishi · 3 shared papers, 2016–2022 · strength 0.29
  4. Satoshi Nara · 3 shared papers, 2016–2022 · strength 0.29
  5. Minoru Esaki · 3 shared papers, 2016–2022 · strength 0.29
  6. Noriteru Doi · 2 shared papers, 2020–2022 · strength 0.28
  7. Shutaro Hori · 3 shared papers, 2016–2020 · strength 0.27
  8. Tomoo Kosuge · 4 shared papers, 2013–2016 · strength 0.19
  9. Utako Ishimoto · 1 shared paper, 2022 · strength 0.14
  10. Kosei Nakajima · 1 shared paper, 2022 · strength 0.14
  11. Hisashi Narimatsu · 1 shared paper, 2020 · strength 0.13
  12. Yuji Heike · 1 shared paper, 2020 · strength 0.10
  13. Toshihiko Torigoe · 1 shared paper, 2020 · strength 0.10
  14. Naoya Nakamura · 1 shared paper, 2020 · strength 0.10
  15. Naoya Kato · 1 shared paper, 2020 · strength 0.09
  16. Toshio Fujisawa · 1 shared paper, 2020 · strength 0.09
  17. Hiroyuki Isayama · 1 shared paper, 2020 · strength 0.09
  18. Raj K. Puri · 1 shared paper, 2020 · strength 0.09
  19. Shin Maeda · 1 shared paper, 2020 · strength 0.09
  20. Atsushi Nakajima · 1 shared paper, 2020 · strength 0.09
  21. Itaru Endo · 1 shared paper, 2020 · strength 0.09
  22. Yoko Shimada · 1 shared paper, 2017 · strength 0.06
  23. Hideyuki Hayashi · 1 shared paper, 2017 · strength 0.06
  24. Hideki Ueno · 1 shared paper, 2017 · strength 0.06
  25. Takuji Okusaka · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.